Genmab — Maj 2020

E_L

interesting daily candle for the TA crowd, green, engulfing, closed yesterdays gap, closed practically equal from yesterday after a 4.5% move. very rare

Legolas23

Its is

Legolas23

Its is a very strong and tough canndle.

E_L

you often see a bullish engulfing candle at a, or signalling a bottom, following a red candle

E_L

we'll see tomorrow what this one means

Helge_LarsenPI-redaktør

Vi har før prøvet tilsvarende kursudvikling på dage med storudsalg af warrants. Hvilke det er husker jeg ikke på stående fod.

transalp

Pokkers.. i morges tippede jeg grøn luk..

GMAB

Conclusions:
SC epcoritamab continues to demonstrate a favorable safety profile across all doses with no ≥Gr 3 CRS and no DLTs. Dose escalation data show improved efficacy as doses reach above the modeled predicted exposure threshold, inducing CRs in heavily pretreated DLBCL pts. All pts achieving CRs remain in remission. Clinical trial information: NCT03625037.

Anti-tumor activity in R/R B-NHL.
DLBCL/HGBCL ≥6 mg (n=12) FL ≥0.76 mg (n=7)
Evaluable pts 9 6
ORR, n(%) CR
PR 5 (56%) 4 (44%)
1 (11%)

E_L

https://meetinglibrary.asco.org/record/186016/abstract

Sukkeralf

Okay looks good - and data will be further updated at the ASCO meeting

E_L

no ≥Gr 3 CRS and no DLTs ; i guess that is the most important for now?

E_L

"Treatment is ongoing in 13 pts " from 41 does not seem much? or should i not read anyting into that?

E_L

then again, very ill patients with 3 to 5 prior lines of treatment.

peter12

Its dose escalation, so I guess not all are evaluated ? 44% CR sounds impressing

gentogen

For a dose escalation study this is crazy good

gentogen

the overall response rate (ORR) after induction treatment with DPd was 100%. ORR on day 100 post ASCT was 100%, 65% achieved ≥CR, and 81% achieved ≥VGPR. There was no treatment related mortality on day 100.

transalp

Go morgen.. der er stadig meget godt i vente..

bibob

God morgen. :-). Ja, og solen skinner

Sukkeralf

Teclistamab (JNJ-64007957)